Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-09-11-Speech-2-376-187"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20120911.32.2-376-187"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spoken text |
"I abstained from this vote as, while it is essential to protect the population from the dangers of medicines and treatments deemed to have dangerous side effects, it is not, in my opinion, an area in which the EU should have jurisdiction. Already in the UK, we have bodies such as NICE to evaluate and test products with any sort of pharmaceutical or pharmacological usage before they are permitted into mainstream medicine. What we need is greater national vigilance against unauthorised and unknown drugs and access to unapproved products on the black market. Some of the EU’s proposals for pharmacovigilance could result in a rise in scaremongering that may, in turn, result in patients not accessing drugs that would otherwise be highly beneficial on the grounds of an unqualified threat. We have already seen the results of parents denying their children vital immunisation due to inconclusive links with autism that were blown out of proportion by the media. There is a real threat that unsubstantiated rumours in one country could result in life-saving medicine being withdrawn across Europe under such legislation."@en1
|
| lpv:spokenAs | |
| lpv:unclassifiedMetadata |
Named graphs describing this resource:
The resource appears as object in 2 triples